Premium
Superselective intra‐arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer
Author(s) -
Mäkelä Jyrki,
Kantola Riitta,
Tikkakoski Tapani,
Siniluoto Topi,
Lein Sami,
Kiviniemi Heikki,
Laitinen Seppo,
Kairaluoma Matti
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199706)65:2<127::aid-jso10>3.0.co;2-2
Subject(s) - medicine , mitomycin c , chemotherapy , colorectal cancer , surgery , cancer , survival rate , gastroenterology , oncology
Background Mitomycin C has been found clinically useful in the treatment of colorectal cancer when administered via the hepatic artery. In a prospective therapeutic trial, we studied the effect of superselective intra‐arterial chemotherapy with mitomycin C in patients with hepatic metastases from colorectal cancer. Methods Forty‐six patients with hepatic metastases from colorectral cancer received intra‐arterial chemotherapy with mitomycin C (SIAC) between 1981 and 1991. The results of a 5‐year follow‐up were compared with 46 control patients standardized by sex, age, and tumor distribution. Results The overall response rate to intra‐arterial chemotherapy was 20%. The median survival time for responders was 26 months and that for nonresponders 12 months ( P < 0.003). The median survival period after intra‐arterial chemotherapy was 15 months, compared with 9 months in controls ( P < 0.004). The cumulative 5‐year survival rate was 6% for patients treated by SIAC and 5% for controls. Cessation of chemotherapy was necessary in 39 of the 46 patients: in 28 because of tumor progression, in 9 because of toxicity, in 1 because of catheterization difficulties, and in 1 because of patient refusal. Conclusions Superselective intra‐arterial mitomycin C therapy had a poor effect on hepatic metastases from colorectal cancer because of the low response and long‐term survival rates. J. Surg. Oncol. 1997;65:127–131. © 1997 Wiley‐Liss, Inc.